Recurrent inactivating RASA2 mutations in melanoma

  • Rand Arafeh (First Author)
  • , Nouar Qutob (Co-Author)
  • , Rafi Emmanuel (Co-Author)
  • , Alona Keren-Paz (Co-Author)
  • , Jason Madore (Co-Author)
  • , Abdel Elkahloun (Co-Author)
  • , James S. Wilmott (Co-Author)
  • , Jared J. Gartner (Co-Author)
  • , Antonella Di Pizio (Co-Author)
  • , Sabina Winograd-Katz (Co-Author)
  • , Sivasish Sindiri (Co-Author)
  • , Ron Rotkopf (Co-Author)
  • , Ken Dutton-Regester (Co-Author)
  • , Peter Johansson (Co-Author)
  • , Antonia L. Pritchard (Co-Author)
  • , Nicola Waddell (Co-Author)
  • , Victoria K. Hill (Co-Author)
  • , Jimmy C. Lin (Co-Author)
  • , Yael Hevroni (Co-Author)
  • , Steven A. Rosenberg (Co-Author)
  • Javed Khan (Co-Author), Shifra Ben-Dor (Co-Author), Masha Y. Niv (Co-Author), Igor Ulitsky (Co-Author), Graham J. Mann (Co-Author), Richard A. Scolyer (Co-Author), Nicholas K. Hayward (Co-Author), Yardena Samuels* (Last Author)
*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

90 Scopus citations

Abstract

Analysis of 501 melanoma exomes identified RASA2, encoding a RasGAP, as a tumor-suppressor gene mutated in 5% of melanomas. Recurrent loss-of-function mutations in RASA2 were found to increase RAS activation, melanoma cell growth and migration. RASA2 expression was lost in ≥30% of human melanomas and was associated with reduced patient survival. These findings identify RASA2 inactivation as a melanoma driver and highlight the importance of RasGAPs in cancer.

Original languageEnglish
Pages (from-to)1408-1410
Number of pages3
JournalNature Genetics
Volume47
Issue number12
DOIs
StatePublished - 1 Dec 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'Recurrent inactivating RASA2 mutations in melanoma'. Together they form a unique fingerprint.

Cite this